- Home
- CLRB vs DLXY Comparison
CLRB vs DLXY Comparison
Compare CLRB & DLXY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CLRB | DLXY |
|---|---|---|
| Founded | 2002 | 2007 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1M | 9.3M |
| IPO Year | 2008 | N/A |
Fundamental Metrics
Financial Performance| Metric | CLRB | DLXY |
|---|---|---|
| Price | $2.83 | $0.72 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | 24.4K | ★ 4.1M |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $11.23 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.23 | $0.45 |
| 52 Week High | $10.19 | $7.00 |
Technical Indicators
Market Signals| Indicator | CLRB | DLXY |
|---|---|---|
| Relative Strength Index (RSI) | 42.08 | 52.80 |
| Support Level | $2.45 | $0.69 |
| Resistance Level | $3.44 | $1.03 |
| Average True Range (ATR) | 0.17 | 0.12 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 13.95 | 53.23 |
Price Performance
Historical ComparisonAbout CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
About DLXY Delixy Holdings Limited Ordinary Shares
Delixy Holdings Ltd a holding company that operates through subsidiary. It is engaged in the trading of oil-related products, which can be categorized into crude oil, and oil-based products such as naphtha, motor gasoline, gas oil, fuel oil, asphalt, base oil, and other petrochemicals. The company has two reportable segments: the Sale of crude oil and the Sale of oil-based products. Key revenue is generated from the Sale of crude oil.